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ARTICLE
Clinical Study
TG01/GM-CSF and adjuvant gemcitabine in patients with
resected RAS-mutant adenocarcinoma of the pancreas
(CT TG01-01): a single-arm, phase 1/2 trial
Daniel H. Palmer1,2, Juan W. Valle 3,4, Yuk Ting Ma5,6, Olusola Faluyi2, John P. Neoptolemos1, Trine Jensen Gjertsen7, Berit Iversen7,
Jon Amund Eriksen7, Anne-Sophie Møller7, Anne-Kirsti Aksnes7, Robert Miller7 and Svein Dueland8
BACKGROUND: TG01 is the first cancer immunotherapy targeting KRAS oncogenic mutations. This study assessed the safety and
efficacy of TG01/GM-CSF in patients with resected pancreatic adenocarcinoma.
METHODS: Patients with stage I or II pancreatic adenocarcinoma who had undergone surgical resection (R0 or R1) received
adjuvant gemcitabine with TG01/GM-CSF using two schedules of vaccination. Immune response was defined as a positive delayed-
type hypersensitivity (DTH) response and/or positive T-cell proliferation assay.
RESULTS: Thirty-two patients were enrolled between February 2013 and May 2016. Nineteen were treated with the high antigen
burden, with four serious adverse reactions considered possibly related to TG01 treatment, including three allergic reactions. On
this basis, a further 13 patients received a modified vaccination schedule with reduced antigen burden, with no serious adverse
events related to TG01. Ninety-five percent patients in the main cohort and 92% in the modified cohort had a positive immune
response. Median overall survival (OS) was 33.1 months, and median disease-free survival (DFS) was 13.9 months for the main
cohort. For the modified cohort, the median OS was 34.3 months and median DFS was 19.5 months.
CONCLUSIONS: TG01/GM-CSF with gemcitabine was well tolerated, with high levels of immune activation. OS and DFS compare
favourably with published data for adjuvant gemcitabine.
CLINICAL TRIAL REGISTRATION: This clinical trial was registered at ClinicalTrials.gov (NCT02261714).
British Journal of Cancer (2020) 122:971–977; https://doi.org/10.1038/s41416-020-0752-7
BACKGROUND
Pancreatic cancer is a major cause of cancer mortality globally,
with a 5-year survival rate <5%. The 5-year survival rate improves
to ~10% in patients who undergo surgical resection, and to ~20%
with the addition of adjuvant chemotherapy. Based on the results
of the ESPAC-3 and CONKO-001 trials,1–3 gemcitabine was
established as adjuvant therapy, with 5-year survival of
~18–20%. In addition, it has been reported that there is no
significant OS difference between patients treated with gemcita-
bine and 5-FU.4 More recently, two clinical trials have demon-
strated a benefit from combination chemotherapy. Firstly, the
ESPAC-4 study showed that the combination of gemcitabine and
capecitabine improved survival compared with gemcitabine alone
(hazard ratio (HR) 0.82 (95% CI, 0.68–0.98), p= 0.032) with 5-year
survival rates of 28.8% vs 16.3% (p= 0.32),5 and this regimen is
now included in the recently implemented ASCO clinical guide-
lines.6 Secondly, the PRODIGE 24/CCTG PA.6 study7 showed that
adjuvant-modified (m)FOLFIRINOX was safe, and significantly
improved disease-free survival (DFS) and overall survival (OS)
when compared with gemcitabine. Median DFS was 12.8 months
in the gemcitabine arm vs 21.6 months in the mFOLFIRINOX arm
(HR= 0.59 (95% CI, 0.47–0.74)), and median OS was 34.8 vs
54.4 months (HR= 0.66 (95% CI, 0.49–0.89)), respectively, such
that mFOLFIRINOX is now also considered a standard of care for
patients sufficiently fit to tolerate this combination. Despite these
recent advances, the majority of resected patients still ultimately
develop disease recurrence, and novel therapies are still required.
The RAS family of human proto-oncogenes encode 21-kD
guanine nucleotide-binding proteins (p21 RAS), which are key
mediators involved in the regulation of cell growth and differentia-
tion. The occurrence of oncogenic mutations in RAS in pancreatic
cancer is very high.8 Moreover, expression of mutated RAS in
different forms of cancer is associated with an overall worse
prognosis and unresponsiveness to treatment.9 The fact that RAS
mutations are expressed in a very high frequency of pancreatic
adenocarcinomas (up to 90%) may be one of the reasons why
standard chemotherapy and new ‘targeted' drugs tested against this
form of cancer have mostly failed to significantly increase survival.
TG01 (Targovax ASA, Oslo, Norway) is the first injectable
antigen-specific cancer immunotherapy (ASCI) targeted to treat
patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)
mutations.10 TG01 consists of a mixture of 7 synthetic RAS
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peptides representing the 7 most common codon 12 and 13
oncogenic mutations in KRAS.
TG01 induces RAS-mutant-specific T-cell responses, which are
enhanced by co-administration of GM-CSF (recombinant human
granulocyte macrophage-colony-stimulating factor (Molgramos-
tim)). The TG01 peptides are 17 amino acids long, and designed to
activate both major histocompatibility complex MHC class II-
restricted CD4+ helper T cells, as well as MHC class I-restricted
CD8+ cytotoxic T cells, which are necessary to sustain the CD8+
cytotoxic T-cell effect.10–12 The activated CD4+ cells are also
important for enhancing/facilitating cross-presentation of tumour
neoantigens and tumour-associated antigens by dendritic cells
(DC) at the site of the tumour, and thus broadening the cytotoxic
CD8+ anticancer activity.
Several studies using one to seven RAS peptides have been
performed previously, without adjuvant chemotherapy (trial
design predating its routine use). Two of the studies using one
or seven of the RAS peptides in patients who had undergone
pancreatic resection were reported in a paper published by
Wedén et al.11 The patients were administered the peptides on
weeks 1, 2, 3, 4, 6 and 10 with boosters weekly for 4 weeks after
3 months or at 3 or 4 months for up to 2 years.
Serious drug reactions were not observed. In the 4-peptide study,
20/34 (58%) of patients mounted an immune response, whereas in
the 7-peptide study (these are the same peptides used for the TG01-
01 study) 12/12 (100%) of patients mounted an immune response.
There were five patients who survived > 5 years, all of whom had
responded to the RAS peptide immunisation.
As a result of these findings, it was concluded that the use of
the seven peptides in future studies would account for the vast
majority of mutations in pancreatic cancer, and that the induction
and booster regimens suggested from these studies would be the
basis of the initial vaccination regimen for the TG01-01 study.
At the time that this was planned, the standard-of-care
chemotherapy used in the adjuvant setting was gemcitabine,
and because it was not known if the use of this agent would
interfere with the patients being able to mount and maintain an
adequate immune response, and because it would not be ethical
to deny patients an adjuvant chemotherapy, the study was
planned to incorporate gemcitabine for up to six cycles starting
within 12 weeks of surgery.
The initial vaccination regimen is based on earlier reported
regimens used for peptide vaccines in clinical trials of pancreatic
cancer.10,11,13,14 TG01 has earlier only been used as monotherapy,
and the regimen was adjusted to include a phase of concurrent
combination with the established adjuvant gemcitabine che-
motherapy for resected pancreatic cancer.
It has been reported that several weekly peptide injections are
required for mounting a detectable immune response, which is
generally not observed until after at least 2–3 weeks of
vaccination.10 For some patients, at least 6 weeks of vaccination
is necessary for mounting a detectable immune response.14
After adjuvant treatment with gemcitabine, the median disease-
free survival of pancreatic cancer patients that have undergone R0
and R1 resection is 14.3–15.2 months measured from surgery.4,5 It
was therefore expected that the majority of the patients of this
study would still be disease-free after completing the adjuvant
gemcitabine treatment (8–9 months after surgery).
This study evaluated the safety, immunological response and
clinical efficacy of TG01/GM-CSF with adjuvant gemcitabine
chemotherapy, which was the standard of care at the time the
study was conducted.
METHODS
Patients
Patients at least 18 years of age with a confirmed diagnosis of stage I
or II adenocarcinoma of the pancreas (according to AJCC staging)
who had undergone successful surgical resection (R0 or R1),
and were expected to receive gemcitabine as adjuvant chemother-
apy within 12 weeks of surgery, were eligible for the study. Patients
had to have acceptable laboratory test results, an Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of 0
or 1 and a life expectancy of at least 6 months.
Patients who had received prior therapy for pancreatic cancer,
including radiation and chemotherapy (except for the primary
resection or primary neoadjuvant chemotherapy), other investiga-
tional drugs within 4 weeks or any agent with a known effect on
the immune system were excluded. Patients with any other
malignancies within the previous 3 years (except for adequately
treated carcinoma of the cervix or basal or squamous cell skin
carcinoma) were also excluded.
The study was conducted at four centres in Norway and the
United Kingdom (UK): Oslo University Hospital, the Clatterbridge
Cancer Centre NHS Foundation Trust, the Christie NHS Foundation
Trust and the Queen Elizabeth Hospital, Birmingham.
Study design
This was a multicentre, phase I/II open-label study to assess the
safety of TG01/GM-CSF vaccination in combination with adjuvant
chemotherapy, and to assess the immune response and clinical
efficacy of TG01/GM-CSF at 2 years in patients with resected
pancreatic adenocarcinoma.
All patients included in the study were scheduled to receive
adjuvant treatment with gemcitabine (note: patients could receive
5-fluorouracil (5-FU) instead of gemcitabine based on laboratory
test results and usual practice at the study centre), and preferably
to start TG01/GM-CSF vaccination at least 3 weeks before the start
of the chemotherapy. Dexamethasone was used as an antiemetic
with chemotherapy. The initial schedule (main cohort) of
vaccination comprised TG01 (0.7 mg of intradermal injection (id))
together with GM-CSF (0.03 mg id) commencing as soon as
possible after surgery, and given on days 1, 3, 5, 8, 15 and 22, and
twice weekly thereafter until the completion of gemcitabine
(starting within 12 weeks of surgery and given as 1000mg/m2 on
days 1, 8 and 15 of a 28-day cycle × 6 cycles). Thereafter, TG01/
GM-CSF was given four weekly up to 1 year, and 12 weekly for up
to 2 years. Four patients in the main cohort started vaccination at
the same time as chemotherapy (i.e. received concomitant
treatment as permitted by the protocol), and received TG01/GM-
CSF on days 1, 3, 5, 8 and 15, and twice weekly thereafter until the
completion of gemcitabine treatment. After 19 patients were
treated, a modified TG01/GM-CSF dosing regimen was introduced.
This was to investigate whether a reduced number of vaccina-
tions, a reduced number of DTH tests used to detect immune
responses and no vaccinations during chemotherapy treatment,
could still induce the same immune responses while improving
the safety profile, particularly with regard to allergic reactions seen
in the main cohort. Patients in the modified cohort also received
TG01/GM-CSF as soon as possible after surgery, administered on
days 1, 8, 15, 22 and 36. Vaccination was then suspended until
completion of gemcitabine treatment (six cycles). Thereafter, TG01
vaccination was given at weeks 4 and 5 post chemotherapy, and
then followed the same schedule as for the main cohort.
Outcomes
The primary outcome measures were safety and immune response.
Safety was assessed by reported adverse events during the entire 2-
year study period. Immune response to TG01 was assessed by two
different antigen-specific assays: (1) delayed-type hypersensitivity
(DTH test), and (2) in vitro T-cell proliferation.
The DTH test (measured up to nine times per patient) is a test in
the skin measuring the presence of activated T cells recognising
TG01. TG01 was injected intradermally, and the DTH test considered
positive if the area of the skin reaction (redness/induration) at the
injection site 48 h after injection had an average diameter ≥ 5mm.
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The T-cell proliferation assay is an in vitro assay showing
proliferation response of TG01-specific T cells. Blood sampling and
peripheral blood mononuclear cell (PBMC) isolation were
performed on day 1 (baseline), week 11, week 52 and at the
end of the study for the main cohort, and on day 1, week 8,
4 weeks after the last chemotherapy injection, week 52 and at the
end of the study for the modified cohort. T-cell responses were
considered positive if the stimulation index (SI) was ≥ 2, indicating
an increase in proliferation of TG01-specific T cells after
stimulation with TG01 compared with unstimulated cells.
An immune responder was defined as having either a positive
DTH response and/or positive T-cell proliferation.
Secondary outcome measures were DFS and OS at 1 and 2 years
measured from the date of surgery. Patients still disease-free at
the last computed tomography (CT) scan collected in the study
were censored on the date of the last CT scan. Patients still alive
when last contacted in the study were censored at the date of the
last contact.
Exploratory endpoints included assessment of the relationship
between KRAS status (in resected primary tumour) and survival
outcomes, and changes in CA19-9 levels.
Statistical analysis
Safety and survival endpoints were analysed by using the All
Treated Patients (ATP) analysis set (defined as patients who
received at least one dose of IMP (TG01, GM-CSF, gemcitabine or
5-FU/leucovorin)). All enrolled patients did receive at least one
dose of IMP. Immune response endpoints were analysed using the
Immune Analysis Set (IAS, defined as patients who provided at
least one set of T-cell and/or DTH response results).
Summary statistics for continuous variables were presented by
the number of patients (n), mean, standard deviation (SD),
median, interquartile range, minimum and maximum. Categorical
variables included frequency counts, and the number and
percentage of patients (n (%)). In general, the denominator for
percentage calculations is the number of patients in the analysis
set. However, for tables by time point the percentages were
calculated by using the number of patients with available data at
that time point.
DFS and OS were estimated using the Kaplan–Meier method,
and are also presented by swimmer plots.
RESULTS
Patients
A total of 32 patients were enrolled between February 2013 and
May 2016, and followed until the last patient included had been in
the study for 3 years. Baseline characteristics are summarised in
Table 1. Nineteen patients were included in the main cohort
(including 4 patients who received concomitant treatment), and
13 patients were included in the modified cohort.
A total of 28 patients discontinued study treatment due to the
following reasons: adverse events (five patients), death (two
patients due to pneumonia and disease progression, not
treatment related), consent withdrawn (four patients) and
investigator decision (two patients). Fifteen patients discontinued
study treatment due to disease recurrence as stipulated in the
protocol.
Thirty one of the 32 patients reported concomitant medical
conditions in addition to pancreatic cancer when they were
included in the study. Overall, the most frequently reported
concomitant medical conditions were hypertension, type 2
diabetes mellitus, constipation, hypercholesterolaemia, gastro-
oesophageal reflux disease and fatigue.
Pathological assessment of the resected specimens showed
that 69% of patients had R1, and 31% had R0 pancreatic
resections.
The initial polymerase chain reaction (PCR) test intended for the
identification of KRAS mutation was performed on biopsy prior to
study enrolment, and showed that 6/32 (19%) patients did not
have a KRAS mutation. However, cancer-related mutant KRAS cell-
free DNA analysis revealed that only 2/32 (6%) did not have KRAS
mutation detected. In conclusion, these results indicate that 30
out of the 32 patients had KRAS mutation.
Treatment
The overall median number of TG01/GM-CSF injections was 14.
Since the number of planned vaccinations was higher for the
main cohort, the median number of injections for this cohort
was 18 compared with 12 for the modified cohort. Patients also
received TG01 (without GM-CSF) for DTH purposes, and the
median numbers of injections for DTH were seven and three for
the main and modified cohort, respectively. The planned
number of DTH tests for the two cohorts were nine and three,
respectively.
The median number of gemcitabine cycles received overall was
six. The median number of cycles for the main and modified
cohorts were four and six, respectively. Two patients in the main
cohort initially received gemcitabine, and subsequently received
5-FU. The reason for changing to 5-FU was for one patient
elevated alanine aminotransferase and the other a SAE of
Table 1. Baseline characteristics.
Parameter Main cohort Modified cohort Overall
(n= 19) (n= 13) (N= 32)
Age (years)
Median (min, max) 67 (49, 79) 59 (46, 74) 65 (46, 79)
Gender, n (%)
Male 10 (53%) 11 (85%) 21 (66%)
Female 9 (47%) 2 (15%) 11 (34%)
ECOG, n (%)
0 8 (42%) 6 (46%) 14 (44%)
1 11 (58%) 7 (54%) 18 (56%)
CA19-9 (U/ml)
Median (min, max) 15 (5, 240) 25 (9, 2166) 16 (5, 2166)
Haemoglobin (g/L)
Median (min, max) 124 (104, 153) 127 (109, 148) 124.5 (104, 153)
Disease staging at diagnosis
T stage
T1 1 (5%) 0 1 (3%)
T2 1 (5%) 0 1 (3%)
T3 17 (90%) 13 (100%) 30 (94%)
N stage
N0 7 (37%) 2 (15%) 9 (28%)
N1 12 (63%) 11 (85%) 23 (72%)
M stage
M0 19 (100%) 13 (100%) 32 (100%)
Resection surgical outcome, n (%)
R0 6 (32%) 4 (31%) 10 (31%)
R1 13 (68%) 9 (69%) 22 (69%)
KRAS mutation detected, n (%)
Yes 16 (84%) 10 (77%) 26 (81%)
No 3 (16%) 3 (23%) 6 (19%)
Time from surgery to the first IMP administration (weeks)
Median (min, max) 8 (7, 12) 9 (7, 12) 9 (7, 12)
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anaphylactic shock related to concomitant medication Aprepitant
(Emend®).
Safety
Twenty treatment-emergent serious adverse events (TESAEs) were
reported in 11/32 patients. Of these, ten serious adverse reactions
(SARs) were reported in 7/32 patients; six reactions were related to
gemcitabine (anaemia, pulmonary infection, pulmonary embolism,
transient ischaemic attack and two fever), three related to TG01
treatment (two anaphylaxes and one hypersensitivity) and one
possibly related to all products (dyspnoea). All the three allergic
reactions related to TG01 treatment occurred after several cycles
of gemcitabine, exclusively in the main cohort, and resolved
within 1–2 h, requiring oral steroids and antihistamines only.
Prophylactic safety measures were implemented in the main
cohort for the ongoing patients after the allergic reactions were
reported. Thereafter, the modified cohort was introduced in the
study, and prophylaxis in this cohort was not required. In the
modified cohort, there were only two serious adverse reactions
(pulmonary embolism and transient ischaemic attack), both
considered related to chemotherapy, and no serious allergic
reactions or SAEs related to TG01 immunotherapy were reported.
In the modified vaccination group, although prophylaxis was
available if the patient experienced an event of hypersensitivity
reaction, this was not required at any stage of the study. There
were no treatment-related deaths in this study.
Of the 528 reported treatment-emergent adverse events
(TEAEs), 90 events in 23 patients were reported to be related to
TG01 immunotherapy. The majority of the TEAEs were related to
Grade 1 and 2 General Disorders and Administration Site
Reactions such as erythema, pruritus, oedema, pain, fatigue and
flu-like symptoms. All related events were Grade 1 or 2, except for
the two reported anaphylactic reactions that were Grade 4. In
total, 61 TEAEs Grade 3 or 4 were reported (Table 2). Gemcitabine
is known to produce skin rash and flu-like symptoms (very
common, ≥ 1/10 according to the summary of product character-
istics), and in the study one event (grade 2) of rash and four events
(grade 1) of influenza-like illness were reported as related to
gemcitabine only.
Immunological response
Immune responses, as detected by a positive DTH test and T-cell
proliferation (SI ≥ 2), are summarised in Table 3. In total, 30/32
(94%) patients had a positive immune response. A total of 18/19
(95%) and 12/13 (92%) patients had a positive immune response
in the main and modified cohorts, respectively.
The high rate of positive immune responses demonstrates that
TG01/GM-CSF vaccination effectively induces TG01-specific T cells
in peripheral blood.
As only two patients were not immune responders, no
correlation with clinical efficacy is possible.
Efficacy
Survival data are summarised in Table 4 and Fig. 1.
For the main cohort, median OS was 33.1 months (95%
confidence interval (CI) 16.8, 45.8), and median DFS was
13.9 months (95% CI 4.5, 21.0). For the modified cohort, median
OS was 34.3 months (95% CI 19.2, 42.5), while median DFS was
19.5 months (95% CI 9.7, not calculable). For the total study
population, median OS was 33.3 months (95% Cl 24.0, 40.0) and
median DFS was 16.1 months (95% CI 11.1–19.6).
A subgroup analysis was performed on the association between
completed chemotherapy and OS. For patients who received five
or six cycles of chemotherapy, the median OS was 45.8, 34.3 and
37.0 months, in the main (n= 11 patients), modified (n= 11
patients) and total (n= 22 patients) study population, respectively.
A swimmer’s plot of DFS and OS is provided in Fig. 2.
Table 2. Treatment-emergent adverse events Grade 3 and 4 by SOC
and preferred term.
SOC Grade 3 Grade 4
Adverse event Patients Events Patients Events
Any adverse event 23 55 5 6
Blood and lymphatic system disorders
Neutropenia 10 11 1 1
Anaemia 1 1
Thrombocytopenia 1 1
Gastrointestinal disorders
Abdominal pain 3 3
Diarrhoea 2 2
Abdominal pain upper 1 1
General disorders and administration site conditions
Fatigue 2 2
Immune system disorders
Anaphylactic reaction 2 2
Anaphylactic shock 1 1
Infections and infestations
Biliary sepsis 1 1
Upper respiratory tract infection 1 1
Urosepsis 1 1
Injury, poisoning and procedural complications
Alcohol poisoning 1 1
Femoral neck fracture 1 1
Investigations
Neutrophil count decreased 6 9 1 1
Haemoglobin decreased 1 1
Platelet count decreased 1 1
Metabolism and nutrition disorders
Hyperglycaemia 1 1 2 2
Diabetes mellitus 1 1
Hyperkalaemia 1 1
Hypokalaemia 1 1
Hyponatraemia 1 1
Nervous system disorders
Coordination abnormal 1 1
Psychiatric disorders
Depression 1 1
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism 2 2
Vascular disorders
Hypertension 7 8
Table 3. Immune response during the entire study period.
Parameters Main cohort
(n= 19)
Modified cohort
(n= 13)
Overall
(N= 32)
Immune
responders
18 (95%) 12 (92%) 30 (94%)
DTH positive 18 (95%) 8 (62%) 26 (81%)
mutRAS-specific
T cells
14 (74%) 12 (92%) 26 (81%)
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DISCUSSION
This study has demonstrated that TG01/GM-CSF vaccination, when
used in conjunction with adjuvant chemotherapy, is generally well
tolerated. The only significant safety finding related to TG01 was
hypersensitivity in some patients, which appeared to be induced
after the patients have received several cycles of chemotherapy
while concurrently receiving TG01 vaccinations. Five patients
(26.3%) in the main cohort experienced TEAEs associated with
allergic reactions; no patients in the modified cohort, with a
reduced antigen burden, and a break from vaccination during
chemotherapy, experienced these types of TEAEs indicating a
more acceptable level of toxicity. It is possible that the total
peptide load of vaccinations plus DTH tests may have contributed
to the risk of hypersensitivity in the main cohort, and it appears
that the mandatory prophylaxis introduced for patients in this
cohort reduced the risk of further severe episodes. A cohort with a
modified vaccination schedule and fewer DTH assessments was
introduced, and this appears to have largely abrogated the risk of
hypersensitivity reactions without the need for prophylaxis, with
no significant reactions reported in patients receiving this
schedule. Some low-grade local reactions, however, were inevi-
tably observed, and likely a sign of immune activation.
The incidence of Grade 4 TEAEs was low in general, with five
patients (26.3%) in the main cohort and no patients in the
modified cohort experiencing these. One patient (main cohort)
died due to a TEAE, pneumonia, which was not considered related
to the investigational medicinal product (IMP). The results of
laboratory assessments did not indicate a clinically significant
difference between the dosing regimens, and the majority of
TEAEs associated with laboratory assessments were considered
related to chemotherapy only.
Ninety-four percent of the patients had at least one reported
immune response during the study period. With the exception of
one patient in the main cohort and one patient in the modified
cohort, all patients had at least one reported immune response.
This high level of immune activation is comparable with immune
activation observed in studies with similar mutant-RAS peptide
vaccination monotherapy,11 which demonstrates that TG01
vaccination can successfully be used in combination with
chemotherapy.
With 3 years of follow-up, the emerging durability data on OS
and DFS in this trial are encouraging when viewed in the context
of current literature reporting large-scale trials with gemcitabine
as monotherapy, which range from 10.7 to 13 months for DFS, and
17.1 to 26.5 months for median survival.4,5,15–19
Based on time from surgery, in this study median DFS was
16.1 months and median OS was 33.3 months for the total study
population, which compare favourably with published data for
gemcitabine monotherapy, and indeed even with gemcitabine
and capecitabine combination therapy (GemCap). Modification of
the vaccination schedule, whilst appearing to eliminate the risk of
allergic reactions, did not appear to compromise this encouraging
efficacy.
A previous study suggested an association between the amount
of chemotherapy and OS.20 In this study, median OS was
28.0 months (CI 26.1, 30.9) for those who completed six cycles
of gemcitabine, or 5-FU and 14.6 months (CI 12.5, 16.9) for those
who received less than six cycles. Our subgroup analysis showed
that a similar trend with median OS for patients receiving five or
six cycles of gemcitabine (or 5-FU) in combination with TG01 was
37.0 months in this subpopulation (n= 22). These findings may
suggest synergism between TG01/GM-CSF and chemotherapy.
In conclusion, this pilot study demonstrated that TG01/GM-CSF
vaccination produces an appropriate immune response, and is
safe to use in conjunction with adjuvant chemotherapy. The study
has also identified the vaccination schedule for future develop-
ment of TG01 in pancreatic cancer in combination with
chemotherapy. The clinical efficacy endpoints of DFS and OST
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compare favourably to historical data reported. Since this study
was conducted, recent clinical trials have demonstrated improved
survival with the use of combination chemotherapy (GemCap or
mFOLFIRINOX) in the adjuvant setting, in patients sufficiently fit to
receive these in the post-operative setting. Nevertheless, the
majority of patients still experience disease recurrence, and further
therapeutic advances are required. Thus, the incorporation of a
safe, well-tolerated, non-cytotoxic agent such as TG01 may be
particularly attractive in this context, and based on the encoura-
ging safety, immunological and efficacy data presented here.
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